Retrospective cohort study (China, 2014-2023, n=4,777 with acute myocardial infarction) in which coronary embolism (CE) was diagnosed via a 3-step validation process (Shibata criteria, angiographic core lab, final adjudication). Patients were grouped: CE with AF (n=78), non-CE AMI with AF (n=205), and non-CE AMI without AF (n=3,937), with propensity-score overlap weighting. CE accounted for 1.6% of all AMIs and 14.7-27.6% of AF-related AMIs. Compared with non-CE AMI without AF, CE+AF patients had significantly higher all-cause mortality (aHR 1.77; 95% CI 1.15-2.71) and ischaemic stroke (aHR 4.45; 95% CI 2.34-8.45), despite 79.2% receiving therapeutic anticoagulation. CE in AF is therefore an underrecognised high-risk phenotype with residual thromboembolic risk. The authors advocate multimodal imaging, embolism-targeted reperfusion, and optimisation of antithrombotic therapy including standard-dose DOACs.
Coronary embolism (CE) is an underrecognized cause of acute myocardial infarction (AMI) in patients with atrial fibrillation (AF). Dedicated management guidelines are lacking because of limited evidence.
This retrospective cohort study leveraged routinely collected electronic health records and regional death registry data from a tertiary hospital in China (2014-2023). Among 4777 patients with AMI, CE was diagnosed using a 3-stage validation process: modified Shibata criteria, blinded angiographic core laboratory assessment, and final adjudication. Patients were categorized into 3 groups: CE with AF (n=78), non-CE AMI with AF (n=205), and non-CE AMI without AF (n=3937). Overlap weighting based on propensity scores was used to balance baseline covariates, and weighted Cox proportional hazards models with competing-risk analysis were applied for comparative outcome analyses.
CE accounted for 1.6% (95% CI, 1.3%-2.0%) of all AMI cases and was present in 14.7% to 27.6% of AF-related AMI. Compared with non-CE AMI patients without AF, those with CE and AF had significantly higher risks of all-cause mortality (overlap-weighted hazard ratio [HR], 1.77 [95% CI, 1.15-2.71]) and ischemic stroke (overlap-weighted HR, 4.45 [95% CI, 2.34-8.45]), despite 79.2% receiving therapeutic anticoagulation.
CE complicating AF represents a high-risk phenotype characterized by high residual thromboembolic risk despite anticoagulation. An integrated management strategy is proposed for future investigation, incorporating multimodal imaging, embolism-targeted reperfusion, and optimization of antithrombotic therapy, including standard-dose direct oral anticoagulants. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06845956.
